Search Results

AceLink Therapeutics, Inc. today announced that the findings from their Phase 1 study of AL01211 in healthy volunteers have been published in the peer-reviewed journal Clinical Pharmacology in Drug Development, a journal of the American College of Clinical Pharmacy.

AceLink Therapeutics, Inc. today announced that Jerry Shen, Ph.D., Chief Executive Officer and Co-Founder of AceLink Therapeutics, will present at the World Orphan Drug Congress Conference.

AceLink Therapeutics, Inc., a clinical-stage biopharmaceutical company developing the next generation of oral substrate reduction therapies (SRTs), announced today that the first patient has been dosed with AL01211 in its Phase 2 trial in China in patients with Fabry disease.

AceLink Therapeutics, Inc. today announced the appointment of Pedro Huertas, M.D., Ph.D., as Chief Medical Officer (CMO).

AceLink Therapeutics, Inc. today announced that it has received clearance from the U.S. Food and Drug Administration (FDA) to initiate a Phase 2 clinical trial of its lead program, AL1211.

AceLink Therapeutics, Inc. announced the opening of the first clinical trial site in China for its Phase 2, open‑label study of the safety, pharmacokinetics, pharmacodynamics and preliminary measures of physiological efficacy of AL01211 in males with classic Fabry disease who have not been previously treated with other Fabry disease therapies.

AceLink Therapeutics, Inc. (AceLink), an innovative biopharmaceutical company developing transformative therapies for genetic diseases, today presented data on the development of AL00804, a novel brain penetrant glucosylceramide synthase inhibitor, to treat Gaucher disease and other neuronopathic glycosphingolipid (GSL) storage diseases.

AceLink Therapeutics, Inc. announced that the company will present two abstracts featuring the development of AL01211 to treat Fabry disease and AL00804 to treat Gaucher disease and other neuronopathic glycosphingolipid storage diseases at the 19th Annual World Symposium Conference, being held in Orlando, Florida, from February 22-26, 2023.

AceLink Therapeutics, Inc. today presented positive data from a Phase 1 trial evaluating the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of AL01211 in healthy volunteers.

AceLink Therapeutics, Inc. (AceLink), an innovative biopharmaceutical company developing transformative therapies for genetic diseases, today announced it has received Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA) for AL01211 as a treatment for Fabry disease.